Document is current

Article History

Received: 14 March 2025

Accepted: 6 May 2025

First Online: 27 May 2025

Declarations

:

: All procedures followed are in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent is obtained from all patients previous to being included in the study.

: F. R. receives speaker honoraria and consultancy fees from Boston, Cordis and Shockwave Medical. P.B. receives speaker honoraria and consultancy fees from AstraZeneca, BMS, Daiichi Sankyo, Novo Nordisk, Pfizer and Sanofi Aventis, and institutional grants from the German Heart Foundation. T.N. is an employee of Novartis Pharma AG. A.K. is one of the inventors in a patent application related to drug-eluting stent technology from his institution of employment. S.T.S. recieved speakers/consulting honoraria from Astra Zeneca, Novartis, Berlin-Chemie, DAIICHI SANKYO, Bristol-Myers-Squibb, Pfizer, Boehringer Ingelheim, Lilly. W. H. received consultancy fees or speaker honoraria from Daiichi Sankyo, Novartis, and Bayer. D.W. received fees from Abiomed, AstraZeneca, Bayer, Boehringer Ingelheim, Berlin-Chemie, Edwards Lifescience, Medtronic, and Novartis. F.J.N. received consultancy honoraria from Novartis and Meril, speaker honoraria from Boston, Amgen, Daiichi-Sankyo and Meril and reports speaker honoraria paid to his institution from BMS/Pfizer, Daiichi-Sankyo, Boston, Siemens, Amgen as well as research grants paid to his institution from Boston and Abbott. CBO reports research support from Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, University of Freiburg, Else Kröner-Fresenius Stiftung, and Haemonetics; Honoraria: Bayer Vital GmbH, BMS, Böhringer Ingelheim, Daiichi Sankyo, Ferrer, Idorsia, and Janssen. M. F. receives speaker honoraria and consultancy fees from Boston, Medtronic and Shockwave Medical. Other authors have nothing to disclose.